156 related articles for article (PubMed ID: 24348818)
21. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
[TBL] [Abstract][Full Text] [Related]
23. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
[TBL] [Abstract][Full Text] [Related]
24. Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report.
Grifasi C; Calogero A; Carlomagno N; Campione S; D'Armiento FP; Renda A
World J Surg Oncol; 2013 Nov; 11():305. PubMed ID: 24279301
[TBL] [Abstract][Full Text] [Related]
25. Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report.
Pedrinaci IZ; Jurado JM; Carrillo J; Molina MC
J Med Case Rep; 2012 Dec; 6():424. PubMed ID: 23253485
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
Jones RL; Maki RG; Patel SR; Wang G; McGowan TA; Shalaby WS; Knoblauch RE; von Mehren M; Demetri GD
Cancer; 2019 Dec; 125(24):4435-4441. PubMed ID: 31503332
[TBL] [Abstract][Full Text] [Related]
27. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
[TBL] [Abstract][Full Text] [Related]
28. Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Langmans C; Cornillie J; van Cann T; Wozniak A; Hompes D; Sciot R; Debiec-Rychter M; Vandenbempt I; Schöffski P
Oncol Res Treat; 2019; 42(7-8):396-404. PubMed ID: 31170709
[TBL] [Abstract][Full Text] [Related]
29. Paratesticular liposarcoma: a clinicopathologic study.
Montgomery E; Fisher C
Am J Surg Pathol; 2003 Jan; 27(1):40-7. PubMed ID: 12502926
[TBL] [Abstract][Full Text] [Related]
30. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
[TBL] [Abstract][Full Text] [Related]
31. Giant primary mesenteric liposarcoma: a rare case report.
Khan N; Afroz N; Fatima U; Raza MH; Rab AZ
Indian J Pathol Microbiol; 2007 Oct; 50(4):787-9. PubMed ID: 18306555
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Response after 94 Cycles of Trabectedin in a Patient with Metastatic Leiomyosarcoma of the Lower Extremity.
Cordeiro M; Casanova JM; Rodrigues J; Freitas J; Fonseca R; Caetano de Oliveira R; Tavares PF
Case Rep Oncol; 2020; 13(1):113-119. PubMed ID: 32231532
[TBL] [Abstract][Full Text] [Related]
33. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
[TBL] [Abstract][Full Text] [Related]
34. Managing Liposarcomas: Cutting Through the Fat.
Manji GA; Schwartz GK
J Oncol Pract; 2016 Mar; 12(3):221-7. PubMed ID: 26962163
[TBL] [Abstract][Full Text] [Related]
35. Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Bello E; Brich S; Craparotta I; Mannarino L; Ballabio S; Gatta R; Marchini S; Carrassa L; Matteo C; Sanfilippo R; Gronchi A; Casali PG; Pilotti S; D'Incalci M; Frapolli R
Br J Cancer; 2019 Sep; 121(6):464-473. PubMed ID: 31409911
[TBL] [Abstract][Full Text] [Related]
36. Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma.
Tamiya H; Sabe H; Yamashita K; Imura Y; Wakamatsu T; Takenaka S
Case Rep Orthop; 2020; 2020():8873185. PubMed ID: 33274094
[TBL] [Abstract][Full Text] [Related]
37. Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist.
Gupta R; Sharma A; Arora R; Kulkarni MP; Chattopadhaya TK; Singh MK
J Gastrointest Cancer; 2010 Mar; 41(1):79-83. PubMed ID: 20058101
[TBL] [Abstract][Full Text] [Related]
38. HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.
Loria R; Laquintana V; Bon G; Trisciuoglio D; Frapolli R; Covello R; Amoreo CA; Ferraresi V; Zoccali C; Novello M; Del Bufalo D; Milella M; Biagini R; D'Incalci M; Falcioni R
Oncogene; 2018 Nov; 37(45):5926-5938. PubMed ID: 29980789
[TBL] [Abstract][Full Text] [Related]
39. [Trabectedin registry].
Kubácková K; Fínek J; Vyzula R; Zvaríková M; Vocka M; Batko S; Dreslerová J; Lazarov PP; Lysý M; Ptátková Z; Benesová V; Bortlícek Z; Kandrnal V
Klin Onkol; 2011; 24(6):470-4. PubMed ID: 22257238
[TBL] [Abstract][Full Text] [Related]
40. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
Barone A; Chi DC; Theoret MR; Chen H; He K; Kufrin D; Helms WS; Subramaniam S; Zhao H; Patel A; Goldberg KB; Keegan P; Pazdur R
Clin Cancer Res; 2017 Dec; 23(24):7448-7453. PubMed ID: 28774898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
